Atlanta, Georgia (PRWEB) October 07, 2012
MissionIR would like to highlight MannKind Corporation, a publicly traded development stage biopharmaceutical company, engaged in the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate, AFREZZA inhalation powder, an ultra rapid-acting insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.
In the company’s news last week,
MannKind announced it has finalized the recruitment of patients for two Phase 3 clinical studies of AFREZZA (insulin human [rDNA origin]), which is an investigational, ultra rapid-acting mealtime insulin therapy administered through the company’s soon-to-be-marketed next-generation inhaler.
Study 171, the first of the two studies, is an open-label study in patients with type 1 diabetes. Following a run-in period, in which all patients will be optimized on their basal insulin regimens, at least 471 subjects will be randomized to one of three arms for mealtime insulin: a control arm, in which patients use injection rapid-acting insulin; or one of two AFREZZA arms – one for the MedTone inhaler and the other for the next-generation inhaler. Once mealtime insulin is titrated, there will be a 12-week observation period on stable doses of the mealtime insulin in order to assess HbA1c levels, which is the main outcome parameter. Another of the study’s objectives is comparing the safety profile of the AFREZZA treatment groups.
Study 175, the second study, will assess AFREZZA using the next-generation inhaler in patients who have type 2 diabetes that is inadequately controlled on metformin, with or without a second or third oral medication. Following a run-in period in which subjects will remain on their oral medications, at least 328 patients will be randomized to additional treatment with AFREZZA or to Technosphere inhalation powder (placebo). This study will additionally have a titration period followed by a 12-week evaluation period to assess HbA1c levels.
Now that patient recruitment – the initial and often lengthiest element in conducting a large-scale Phase 3 clinical trial – is completed, both studies are on track to be completed in the second quarter of 2013. Topline results are expected next summer. After that, the company’s objective is to resubmit the NDA for AFREZZA in the third quarter of 2013.
MannKind is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutic products for patients with diseases like diabetes and cancer. The company’s lead product, AFREZZA, is in late-stage clinical investigation for treating adults with type 1 or type 2 diabetes for the control of hyperglycemia.
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
To sign up for The MissionIR Report, please visit http://MissionIR.com
To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR
To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR
Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.